Section Arrow
BIVI.NASDAQ
- BioVie Inc
Quotes are at least 15-min delayed:2026/08/31 09:33 EDT
Regular Hours
Last
 2.3599
+0.1999 (+9.25%)
Day High 
2.39 
Prev. Close
2.16 
1-M High
3.79 
Volume 
91.29K 
Bid
2.32
Ask
2.36
Day Low
2.297 
Open
2.374 
1-M Low
0.82 
Market Cap 
18.25M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.8 
20-SMA 1.64 
50-SMA 1.71 
52-W High 3.79 
52-W Low 0.82 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.05/-2.95
Enterprise Value
18.44M
Balance Sheet
Book Value Per Share
1.22
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
AIMAIM ImmunoTech Inc.0.3342+0.0758+29.33%-- 
MRNAModerna136.34-1.65-1.20%-- 
SLSSELLAS Life Sciences Group13.135-0.075-0.57%-- 
IOVAIovance Biotherapeutics7.8201-0.1899-2.37%-- 
ARTLArtelo Biosciences Inc5.55-0.4143-6.95%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.